Annual Total Liabilities
$12.51 M
+$6.49 M+107.89%
31 December 2022
Summary:
Navidea Biopharmaceuticals annual total liabilities is currently $12.51 million, with the most recent change of +$6.49 million (+107.89%) on 31 December 2022. During the last 3 years, it has risen by +$6.80 million (+119.13%). NAVB annual total liabilities is now -84.38% below its all-time high of $80.13 million, reached on 31 December 2016.NAVB Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$8.68 M
-$327.60 K-3.64%
30 September 2023
Summary:
Navidea Biopharmaceuticals quarterly total liabilities is currently $8.68 million, with the most recent change of -$327.60 thousand (-3.64%) on 30 September 2023. NAVB quarterly total liabilities is now -89.17% below its all-time high of $80.13 million, reached on 31 December 2016.NAVB Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NAVB Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | +119.1% | +79.8% |
| 5 y5 years | +171.4% | +76.6% |
NAVB Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +119.1% | -30.6% | +79.8% |
| 5 y | 5 years | at high | +171.4% | -30.6% | +79.8% |
| alltime | all time | -84.4% | +1985.8% | -89.2% | +2069.7% |
Navidea Biopharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $8.68 M(-3.6%) |
| June 2023 | - | $9.01 M(-24.4%) |
| Mar 2023 | - | $11.92 M(-4.8%) |
| Dec 2022 | $12.51 M(+107.9%) | $12.51 M(+14.5%) |
| Sept 2022 | - | $10.93 M(+62.0%) |
| June 2022 | - | $6.74 M(+18.1%) |
| Mar 2022 | - | $5.71 M(-5.1%) |
| Dec 2021 | $6.02 M(+5.4%) | $6.02 M(+24.8%) |
| Sept 2021 | - | $4.83 M(-0.4%) |
| June 2021 | - | $4.85 M(-4.4%) |
| Mar 2021 | - | $5.07 M(-11.3%) |
| Dec 2020 | $5.71 M(+13.5%) | $5.71 M(+12.1%) |
| Sept 2020 | - | $5.09 M(-41.6%) |
| June 2020 | - | $8.73 M(+56.8%) |
| Mar 2020 | - | $5.57 M(+10.7%) |
| Dec 2019 | $5.03 M(+9.1%) | $5.03 M(+2.4%) |
| Sept 2019 | - | $4.91 M(-5.5%) |
| June 2019 | - | $5.20 M(+6.9%) |
| Mar 2019 | - | $4.87 M(+5.5%) |
| Dec 2018 | $4.61 M(-47.2%) | $4.61 M(-35.0%) |
| Sept 2018 | - | $7.10 M(+20.9%) |
| June 2018 | - | $5.87 M(-56.1%) |
| Mar 2018 | - | $13.37 M(+53.1%) |
| Dec 2017 | $8.73 M(-89.1%) | $8.73 M(+32.5%) |
| Sept 2017 | - | $6.59 M(-23.0%) |
| June 2017 | - | $8.56 M(-18.9%) |
| Mar 2017 | - | $10.56 M(-86.8%) |
| Dec 2016 | $80.13 M(+16.5%) | $80.13 M(+6.9%) |
| Sept 2016 | - | $74.96 M(+3.3%) |
| June 2016 | - | $72.59 M(+4.5%) |
| Mar 2016 | - | $69.44 M(+0.9%) |
| Dec 2015 | $68.80 M(+65.3%) | $68.80 M(-0.7%) |
| Sept 2015 | - | $69.30 M(+3.7%) |
| June 2015 | - | $66.82 M(+44.4%) |
| Mar 2015 | - | $46.28 M(+11.2%) |
| Dec 2014 | $41.63 M(-6.1%) | $41.63 M(-14.9%) |
| Sept 2014 | - | $48.90 M(+3.1%) |
| June 2014 | - | $47.42 M(+0.4%) |
| Mar 2014 | - | $47.25 M(+6.6%) |
| Dec 2013 | $44.33 M(+231.3%) | $44.33 M(+7.9%) |
| Sept 2013 | - | $41.07 M(+24.7%) |
| June 2013 | - | $32.95 M(+101.8%) |
| Mar 2013 | - | $16.32 M(+22.0%) |
| Dec 2012 | $13.38 M(+33.0%) | $13.38 M(+23.3%) |
| Sept 2012 | - | $10.85 M(+7.6%) |
| June 2012 | - | $10.09 M(+0.7%) |
| Mar 2012 | - | $10.02 M(-0.4%) |
| Dec 2011 | $10.06 M(+49.5%) | $10.06 M(+105.6%) |
| Sept 2011 | - | $4.89 M(-17.2%) |
| June 2011 | - | $5.91 M(+9.7%) |
| Mar 2011 | - | $5.39 M(-20.0%) |
| Dec 2010 | $6.73 M(-64.4%) | $6.73 M(+14.6%) |
| Sept 2010 | - | $5.87 M(+13.2%) |
| June 2010 | - | $5.19 M(-74.5%) |
| Mar 2010 | - | $20.30 M(+7.5%) |
| Dec 2009 | $18.89 M(+49.4%) | $18.89 M(-3.6%) |
| Sept 2009 | - | $19.60 M(-47.5%) |
| June 2009 | - | $37.34 M(+54.7%) |
| Mar 2009 | - | $24.13 M(+90.8%) |
| Dec 2008 | $12.65 M | $12.65 M(+39.5%) |
| Sept 2008 | - | $9.06 M(+5.9%) |
| June 2008 | - | $8.56 M(+4.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $8.21 M(-25.4%) |
| Dec 2007 | $11.01 M(+32.1%) | $11.01 M(+35.2%) |
| Sept 2007 | - | $8.14 M(+0.9%) |
| June 2007 | - | $8.07 M(-1.6%) |
| Mar 2007 | - | $8.20 M(-1.6%) |
| Dec 2006 | $8.33 M(+10.3%) | $8.33 M(+11.1%) |
| Sept 2006 | - | $7.50 M(+3.9%) |
| June 2006 | - | $7.22 M(-1.8%) |
| Mar 2006 | - | $7.35 M(-2.7%) |
| Dec 2005 | $7.55 M(-17.9%) | $7.55 M(+8.4%) |
| Sept 2005 | - | $6.97 M(-2.0%) |
| June 2005 | - | $7.11 M(+4.5%) |
| Mar 2005 | - | $6.80 M(-26.1%) |
| Dec 2004 | $9.20 M(+332.8%) | $9.20 M(+793.8%) |
| Sept 2004 | - | $1.03 M(-22.5%) |
| June 2004 | - | $1.33 M(-17.8%) |
| Mar 2004 | - | $1.62 M(-24.0%) |
| Dec 2003 | $2.13 M(-31.8%) | $2.13 M(-33.6%) |
| Sept 2003 | - | $3.20 M(+5.4%) |
| June 2003 | - | $3.04 M(+15.5%) |
| Mar 2003 | - | $2.63 M(-15.7%) |
| Dec 2002 | $3.12 M(-29.5%) | $3.12 M(-40.3%) |
| Sept 2002 | - | $5.23 M(+10.5%) |
| June 2002 | - | $4.73 M(+21.9%) |
| Mar 2002 | - | $3.88 M(-12.3%) |
| Dec 2001 | $4.43 M(-4.0%) | $4.43 M(+6.3%) |
| Sept 2001 | - | $4.16 M(+8.1%) |
| June 2001 | - | $3.85 M(-3.5%) |
| Mar 2001 | - | $3.99 M(-13.5%) |
| Dec 2000 | $4.61 M(-56.0%) | $4.61 M(+8.1%) |
| Sept 2000 | - | $4.26 M(-23.5%) |
| June 2000 | - | $5.57 M(+1.7%) |
| Mar 2000 | - | $5.48 M(+5.4%) |
| Dec 1999 | $10.46 M(+45.9%) | - |
| June 1999 | - | $5.20 M(-8.8%) |
| Mar 1999 | - | $5.70 M(-20.5%) |
| Dec 1998 | $7.17 M(-20.5%) | $7.17 M(-18.5%) |
| Sept 1998 | - | $8.80 M(-6.4%) |
| June 1998 | - | $9.40 M(-10.5%) |
| Mar 1998 | - | $10.50 M(+16.4%) |
| Dec 1997 | $9.02 M(+4.9%) | $9.02 M(-7.0%) |
| Sept 1997 | - | $9.70 M(+6.6%) |
| June 1997 | - | $9.10 M(+40.0%) |
| Mar 1997 | - | $6.50 M(-24.4%) |
| Dec 1996 | $8.60 M(+109.8%) | $8.60 M(+87.0%) |
| Sept 1996 | - | $4.60 M(+48.4%) |
| June 1996 | - | $3.10 M(+10.7%) |
| Mar 1996 | - | $2.80 M(-31.7%) |
| Dec 1995 | $4.10 M(0.0%) | $4.10 M(+28.1%) |
| Sept 1995 | - | $3.20 M(+68.4%) |
| June 1995 | - | $1.90 M(-13.6%) |
| Mar 1995 | - | $2.20 M(-46.3%) |
| Dec 1994 | $4.10 M(+127.8%) | $4.10 M(+86.4%) |
| Sept 1994 | - | $2.20 M(+37.5%) |
| June 1994 | - | $1.60 M(-20.0%) |
| Mar 1994 | - | $2.00 M(+11.1%) |
| Dec 1993 | $1.80 M(+200.0%) | $1.80 M(+28.6%) |
| Sept 1993 | - | $1.40 M(+133.3%) |
| June 1993 | - | $600.00 K(0.0%) |
| Mar 1993 | - | $600.00 K(0.0%) |
| Dec 1992 | $600.00 K | $600.00 K(+50.0%) |
| Sept 1992 | - | $400.00 K |
FAQ
- What is Navidea Biopharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Navidea Biopharmaceuticals?
What is Navidea Biopharmaceuticals annual total liabilities?
The current annual total liabilities of NAVB is $12.51 M
What is the all time high annual total liabilities for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual total liabilities is $80.13 M
What is Navidea Biopharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of NAVB is $8.68 M
What is the all time high quarterly total liabilities for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly total liabilities is $80.13 M